Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at ...

Move comes 2 years after controversial exit of brand-name product ...

Noticing a receding hairline? You’re not alone — and thanks to years of research, effective treatments are within reach. Male ...

The FDA approved a vaccine for mumps nearly 60 years ago, so why are some areas of the United States experiencing outbreaks ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...

The month of Ramadan, which began last week, is when many Muslims around the world fast from dawn to sunset, refraining from ...

Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the ...

Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi (R) for the treatment of adults with polycythemia vera (PV). The Company is seeking a ropeginterferon alfa-2b-njft label ...

New regimen for ropeginterferon alfa2b-njft enables patients to reach target dose faster, supporting positive clinical ...

Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...

We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Coinbase wins for its strong U.S. compliance and beginner-friendly interface Gloria ...

Alexion, AstraZeneca Rare Disease's Ultomiris® (ravulizumab rch) has been listed on the Pharmaceutical Benefits Scheme (PBS) for adults with ...